A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Study Summary

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.

Conditions

T-cell Lymphoma

Interventions / Drugs

CPI-818

View on ClinicalTrials.gov ↗

Sponsor

CRVS

Corvus Pharmaceuticals

Oncology

D49/100

Study Details

Enrollment151 participants

Primary Completion—

Lead SponsorCorvus Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:10:54.089187+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.